DDR1 and cancer: Other than TKIs, 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides have been identified as selective DDR1 inhibitors with a relatively low IC50 and could potently attenuate cancer invasion, adhesion, and tumorigenesis in vitro509.